🔗 Share this article World Health Organization Raises Warning Over Severe Shortage of Weight-Loss Medications Fewer than one in 10 individuals who could benefit from weight-loss injections including Wegovy can access them, warns the World Health Organization as it releases its first guidance on the medications. Considering more than one billion people worldwide now classified as obese, it is advocating for more widespread and fairer access to this class of drugs. Per estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken. "The new guidelines acknowledges that excess weight is a long-term condition that can be addressed with comprehensive and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are significant barriers to universal availability to the jabs that can help people shift significant body mass, explains the body. GLP-1 Therapy Shortage Even under the present most optimistic outlook, the production of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, as stated by the health organization. The guideline encourages countries and companies to expand availability, through strategies including voluntary licensing. A patent on semaglutide – the primary component of a leading brand – is due to expire in multiple nations in 2026. How Obesity Injections Operate The injections imitate a biological compound to slow digestion, suppress the appetite and increase satiety so people consume fewer calories. Patients commonly see weight reduction in the initial weeks of starting on the regular doses. Studies suggests patients may put most of the weight back on within a year of discontinuing the medication, when their typical food cravings resume. Being carrying excess weight increases your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some cancers. Excess weight affects people in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.
Fewer than one in 10 individuals who could benefit from weight-loss injections including Wegovy can access them, warns the World Health Organization as it releases its first guidance on the medications. Considering more than one billion people worldwide now classified as obese, it is advocating for more widespread and fairer access to this class of drugs. Per estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken. "The new guidelines acknowledges that excess weight is a long-term condition that can be addressed with comprehensive and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and distribution challenges are significant barriers to universal availability to the jabs that can help people shift significant body mass, explains the body. GLP-1 Therapy Shortage Even under the present most optimistic outlook, the production of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, as stated by the health organization. The guideline encourages countries and companies to expand availability, through strategies including voluntary licensing. A patent on semaglutide – the primary component of a leading brand – is due to expire in multiple nations in 2026. How Obesity Injections Operate The injections imitate a biological compound to slow digestion, suppress the appetite and increase satiety so people consume fewer calories. Patients commonly see weight reduction in the initial weeks of starting on the regular doses. Studies suggests patients may put most of the weight back on within a year of discontinuing the medication, when their typical food cravings resume. Being carrying excess weight increases your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some cancers. Excess weight affects people in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.